Conference Detail



View All Family Medicine Conferences Post a Conference Calendar Map Conference Coverage

Family Medicine Conference Details

Bone Health 2014 CME

Date:
March 29, 2014
Location:
Dallas, Texas 75390, United States
Description:
The aim of this symposium is to provide the latest knowledge and discuss controversies related to the pathogenesis and management of primary osteoporosis and drug-induced osteoporosis as well as covering current topics on mineral disorders in special populations such as patients with chronic kidney disease or kidney stones. The format of this symposium will be a series of lectures presented by experts in the field on a variety of topics followed by panel discussions where the audience can directly interact with the speakers.

7.25 AMA PRA Category 1 Credits™ - maximum

Venue: UT Southwestern Medical Center
Conference Full List

Prepare for This Meeting

Read Article Summaries From Top Medical Journals

1 Kidney stones and cardiovascular events: A cohort study Clinical Journal of the American Society of Nephrology, December 9, 2013

2 Use of pharmacologic agents for the primary prevention of osteoporosis among older women with low bone mass Osteoporosis International, January 2, 2014

3 Pathogenesis of alcohol-induced osteoporosis and its treatment: A review Current Drug Targets, December 19, 2013 Review Article

4 Soda and other beverages and the risk of kidney stones Clinical Journal of the American Society of Nephrology, August 8, 2013

5 Concern and risk perception of osteoporosis and fracture among post-menopausal Australian women: results from the Global Longitudinal Study of Osteoporosis in Women (GLOW) cohort Archives of Osteoporosis, October 11, 2013 Evidence Based Medicine

Related Quizzes From Smartest Doc

Question: Coffee has been suggested to contribute to the development of osteoporotic fractures. According to a recent study, what effect does high coffee consumption (4 or more cups/day) have in women over the age of 65?

Question: Which is NOT true about odanacatib, an investigational agent for osteoporosis?

Question: Which outcome is significantly greater with daily teriparatide in patients with postmenopausal osteoporosis and RA compared to those with only postmenopausal osteoporosis?

Latest Family Med Articles